NeoVax(MI) vaccine developed by Dana-Farber Cancer Institute could be approved soon with promising results in boosting immune response in melanoma patients
Lara Maior
Health
Vyacheslav Lopatin / Alamy / Profimedia
Always see our news on Google
The clinical trial of the personalized vaccine NeoVax(MI) has shown promising results in the treatment of melanoma, generating a strong immune response. The vaccine contains patient-specific neoantigens and is administered together with standard immunotherapies such as nivolumab and ipilimumab. Scientists observed an increase in immune cells after vaccination, indicating effective immune activation. This innovative approach could significantly improve treatments for skin cancer.
Sources
Vaccinul contra unui tip agresiv de cancer, la un pas de a intra pe piață. Rezultatele remarcabile dau speranțe pacienților
Consiliul Concurenței analizează tranzacţia prin care Mehiläinen Oy preia rețeaua de centre mediale Regina Maria
Consiliul Concurenţei analizează preluarea Grupului Regina Maria de către Mehiläinen Oy
Latest News
18:55
PSD accuses the USR prefect from Timiș of abuse of office to maintain the mandate of mayor Dominic Fritz
18:42
Eight electric bicycles valued at 20,000 euros, discovered by border police in Borș
18:40
A 43-year-old woman has been placed in preventive detention in Constanța for attempted drug trafficking.
18:29
Radu Miruță announces that the subway circulation in Bucharest will not be affected by energy restrictions.
18:19
The large stores in Romania are implementing energy-saving measures, such as limiting air conditioning and turning off advertising lights at night.
See more news
NEWS ON THE SAME TOPICS
.webp)
.webp)
Personalized news feed, AI-powered search, and notifications in a more interactive experience.
